Table of contents:

Committee papers (appendices 1-3)

1. Overview
3. Assessment report ScHARR

Committee papers (appendices 4-11)

4a. Comments on the Assessment Report AbbVie
4b. Comments on the Assessment Report BMS
4c. Comments on the Assessment Report MSD
4c. Comments on the Assessment Report MSD
4d. Comments on the Assessment Report Pfizer
4e. Comments on the Assessment Report Roche
4f. Comments on the Assessment Report UCB
4g. Comments on the Assessment Report ARMA
4h. Comments on the Assessment Report NRSA
4i. Comments on the Assessment Report RCN
4j. Comments on the Assessment Report HIS
5. Expert comments on the Assessment report BSR CDeighton and FMcKenna
6. Response to consultee and commentator comments on the Assessment Report ScHARR
7a. Executive summary of technology manufacturer's submission AbbVie
7b. Executive summary of technology manufacturer's submission BMS
7c. Executive summary of technology manufacturer's submission MSD golimumab
7d. Executive summary of technology manufacturer's submission MSD infliximab
7e. Executive summary of technology manufacturer's submission - Pfizer
7f. Executive summary of technology manufacturer's submission - Roche
7g. Executive summary of technology manufacturer's submission - UCB
8a. Consultee submission Arthritis Care</p> <p>8b. Consultee submission BSR endorsed by RCP and ARMA
8c. Consultee Submission NRAS
8d. Consultee submission RCN
9a. Patient Expert statement ABosworth
9b. Clinical Expert statement CDeighton
9c. Patient Expert statement DMcWilliam
9d. Clinical Expert statement FMcKenna
10. Erratum to Assessment Report ScHARR
11a Abbvie comments on AG model_Dec2013
11b. BMS comments on AG model_Dec2013
11c. Pfizer comments on AG model_Dec2013
11d. MSD comments on AG model_Dec2013
11e. Roche Comments on AG model_Dec2013
11e.i Roche additional comments on AG model_Dec2013
11f. UCB comments on AG model_Dec2013
11g. RCPath comments on AG model_Dec2013

Committee papers (appendix 12)

12a. Assessment report addendum
12b. Appendix 1 Updated Assessment Report

Committee papers (appendices 13-19)

13. DSU report HAQ progression
14. AG report impact of DSU report HAQ progression on clinical and cost effectiveness
15a. Comments on the DSU Report and Assessment Report ABBVIE
15b. Comments on the DSU Report and Assessment Report BMS
15c. Comments on the DSU Report and Assessment Report Pfizer
15d. Comments on the DSU Report and Assessment Report MSD
15e. Comments on the DSU Report and Assessment Report Roche
15f. Comments on the DSU Report and Assessment Report Napp
15g. Comments on the DSU Report and Assessment Report BSR
15h. Comments on the DSU Report and Assessment Report NRAS
15h.i. NRAS Appendix 1 NRAS Survey
15h.ii. NRAS Appendix 2_CaseStudiesFreeTextResp
15i. Comments on the DSU Report and Assessment Report RCPath
16. Comments on economic model Pfizer
17. Revised ICERs following the correction of identified errors prepared ScHARR
18. Exploratory analyses following comments received in April 2015 ScHARR
19. DSU response to comments received on DSU consultation